ETA receptor antagonists inhibit allergic inflammation in the mouse

J Cardiovasc Pharmacol. 1995:26 Suppl 3:S416-8.

Abstract

This study investigated the influence of the selective endothelin (ET) ETA receptor antagonists BQ-123 and FR 139317 on paw edema induced by ovalbumin (OVA) injection (3 micrograms/paw) to OVA-sensitized mice [50 micrograms in 5 mg of Al(OH)3, s.c., 14 days earlier]. Injections of BQ-123 (1.5, 15, and 150 pmol/paw, 15 min earlier) reduced OVA-induced edema from 59.6 +/- 4.0 to 48.3 +/- 5.4, 44.6 +/- 3.8, and 34 +/- 2.0 microliters, respectively (p < 0.05; n = 6). Like BQ-123, FR 139317 (7.5, 75, and 750 pmol/paw) also inhibited OVA-induced edema in a graded fashion but was less potent. In contrast, BQ-123 (150 pmol/paw) failed to affect paw edema induced in nonsensitized mice by histamine (100 micrograms/paw), serotonin (100 micrograms/paw), or zymosan (500 micrograms/paw), but significantly reduced edema induced by carrageenan (300 micrograms/paw) by 30% (p < 0.05). These results strongly suggest that endogenous ETs, acting through ETA receptors, play an important proinflammatory role in the allergic reaction to OVA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azepines / therapeutic use*
  • Edema / etiology
  • Edema / prevention & control*
  • Endothelin Receptor Antagonists*
  • Endothelins / physiology
  • Indoles / therapeutic use*
  • Male
  • Mice
  • Ovalbumin / immunology
  • Peptides, Cyclic / therapeutic use*
  • Receptor, Endothelin A

Substances

  • Azepines
  • Endothelin Receptor Antagonists
  • Endothelins
  • Indoles
  • Peptides, Cyclic
  • Receptor, Endothelin A
  • FR 139317
  • Ovalbumin
  • cyclo(Trp-Asp-Pro-Val-Leu)